Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Alessandra Audia, Gregory Bannish, Rachel Bunting & Chelsea Riveley. (2022) Flow cytometry and receptor occupancy in immune-oncology. Expert Opinion on Biological Therapy 22:1, pages 87-94.
Read now
Read now
Eleni Karatza, George Ismailos, Markos Marangos & Vangelis Karalis. (2021) Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteristics: a review of the literature and simulations. Xenobiotica 51:2, pages 127-138.
Read now
Read now
Ulrich Kronthaler, Cornelius Fritsch, Otmar Hainzl, Andreas Seidl & Antonio da Silva. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opinion on Biological Therapy 18:8, pages 921-930.
Read now
Read now
Patrick M. Glassman & Joseph P. Balthasar. (2017) Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. mAbs 9:2, pages 297-306.
Read now
Read now
Hoon Young Suh, Carl C Peck, Kyung-Sang Yu & Howard Lee. (2016) Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Design, Development and Therapy 10, pages 4005-4016.
Read now
Read now
Jean W Lee & Hossein Salimi-Moosavi. (2012) Bioanalysis of Target Biomarker And Pk/Pd Relevancy During The Development of Biotherapeutics. Bioanalysis 4:20, pages 2513-2523.
Read now
Read now
Rong Deng, Feng Jin, Saileta Prabhu & Suhasini Iyer. (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. Expert Opinion on Drug Metabolism & Toxicology 8:2, pages 141-160.
Read now
Read now
Frank R. Brennan, Laura Dill Morton, Sebastian Spindeldreher, Andrea Kiessling, Roy Allenspach, Adam Hey, Patrick Müller, Werner Frings & Jennifer Sims. (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 2:3, pages 233-255.
Read now
Read now
Thierry Lavé, Kathryn Chapman, Paul Goldsmith & Malcolm Rowland. (2009) Human clearance prediction: shifting the paradigm. Expert Opinion on Drug Metabolism & Toxicology 5:9, pages 1039-1048.
Read now
Read now
Masoud Jamei, Steve Marciniak, Kairui Feng, Adrian Barnett, Geoffrey Tucker & Amin Rostami-Hodjegan. (2009) The Simcyp® Population-based ADME Simulator. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 211-223.
Read now
Read now
Articles from other publishers (66)
Simranjit Kaur, Muktika Tekade, Nupur Vasdev, Bhakti Pawar, Tanisha Gupta, Aprameya Ganesh Prasad & Rakesh Kumar Tekade. 2024. Public Health and Toxicology Issues Drug Research, Volume 2. Public Health and Toxicology Issues Drug Research, Volume 2
205
224
.
Elisabeth Koch & Stephanie Plassmann. 2024. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
9
47
.
Ha-Lim Song, Na-Young Kim, Jaewan Park, Meong Il Kim, Yu-Na Jeon, Se-Jong Lee, Kwangmin Cho, Young-Lim Shim, Kyoung-Hye Lee, Yeon-Seon Mun, Jung-A Song, Min-Seok Kim, Chan-Gi Pack, Minkyo Jung, Hyemin Jang, Duk L. Na, Minsun Hong, Dong-Hou Kim & Seung-Yong Yoon. (2023) Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280–acetylated tau in cell and mouse models. Journal of Clinical Investigation 133:8.
Crossref
Crossref
Yichen Feng, Kenneth M. Tichauer & Kimberley S. Samkoe. (2023) Development of near-infrared paired-agent imaging for in vivo quantification of drug receptor occupancy in tumor. Development of near-infrared paired-agent imaging for in vivo quantification of drug receptor occupancy in tumor.
Christine Grimaldi, Alex Ibraghimov, Andrea Kiessling, Benno Rattel, Changhua Ji, Claudette L. Fuller, Frank R. Brennan, Franziska Regenass-Lechner, Jacintha Shenton, Karen D. Price, Marie-Soleil Piché, Meredith A. Steeves, Rodney Prell, Sherri Dudal, Sven Kronenberg, Wendy Freebern & Diann Blanset. (2023) Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discovery Today 28:2, pages 103440.
Crossref
Crossref
Dong Wook Kang, Ju Hee Kim & Hea-Young Cho. (2023) Approaches for estimating the clinical starting dose of new dosage forms: An example of a long-acting injectable formulation of finasteride. International Journal of Pharmaceutics 631, pages 122510.
Crossref
Crossref
Kirit Singh, John H. Sampson & Patrick C. Gedeon. 2023. Translational Surgery. Translational Surgery
43
51
.
Youssef Hijazi. (2022) Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models. European Journal of Clinical Pharmacology 79:1, pages 137-147.
Crossref
Crossref
Shamir N. Kalaria, Hechuan Wang & Jogarao V. Gobburu. 2022. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1937
1960
.
Maribel G. Vallespi, Braulio Mestre, Maria A. Marrero, Rolando Uranga, Diana Rey, Martha Lugiollo, Mircea Betancourt, Kirenia Silva, Danay Corrales, Yanet Lamadrid, Yamilka Rodriguez, Anaelys Maceo, Pedro P. Chaviano, Gilda Lemos, Ania Cabrales, Freya M. Freyre, Hector Santana, Hilda E. Garay, Brizaida Oliva & Julio R. Fernandez. (2021)
A first‐in‐class, first‐in‐human, phase I trial of
CIGB
‐552, a synthetic peptide targeting
COMMD1
to inhibit the oncogenic activity of
NF‐κB
in patients with advanced solid tumors
. International Journal of Cancer 149:6, pages 1313-1321.
Crossref
Crossref
Michael W. Leach, David O. Clarke, Sherri Dudal, Chao Han, Chunze Li, Zheng Yang, Frank R. Brennan, Wendy J. Bailey, Yingxue Chen, Antoine Deslandes, Lise I. Loberg, Kapil Mayawala, Mark C. Rogge, Marque Todd & Nagendra V. Chemuturi. (2020) Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment. Clinical Pharmacology & Therapeutics 109:6, pages 1395-1416.
Crossref
Crossref
Tomás Sou, Jon Hansen, Edgars Liepinsh, Maria Backlund, Onur Ercan, Solveiga Grinberga, Sha Cao, Paraskevi Giachou, Anna Petersson, Magdalena Tomczak, Malgorzata Urbas, Dorota Zabicka, Carina Vingsbo Lundberg, Diarmaid Hughes, Sven N. Hobbie & Lena E. Friberg. (2020) Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. Clinical Pharmacology & Therapeutics 109:4, pages 1063-1073.
Crossref
Crossref
Danijela Đukić-Ćosić, Katarina Baralić, Dragica Jorgovanović, Katarina Živančević, Dragana Javorac, Nikola Stojilković, Biljana Radović, Đurđica Marić, Marijana Ćurčić, Aleksandra Buha-Đorđević, Zorica Bulat, Evica Antonijević-Miljaković & Biljana Antonijević. (2021) 'In silico' toxicology methods in drug safety assessment. Arhiv za farmaciju 71:4, pages 257-278.
Crossref
Crossref
Pradeep Sharma, Nikunjkumar Patel, Bhagwat Prasad & Manthena V. S. Varma. 2021. Drug Discovery and Development. Drug Discovery and Development
297
355
.
Archana Mishra, Sudhir Chandra Sarangi & Kh Reeta. (2020) First-in-human dose: current status review for better future perspectives. European Journal of Clinical Pharmacology 76:9, pages 1237-1243.
Crossref
Crossref
Teilo H Schaller, David J Snyder, Ivan Spasojevic, Patrick C Gedeon, Luis Sanchez-Perez & John H Sampson. (2020) First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. Journal for ImmunoTherapy of Cancer 8:1, pages e000213.
Crossref
Crossref
Shamir N. Kalaria, Hechuan Wang & Jogarao V. Gobburu. 2020. Principles and Practice of Clinical Trials. Principles and Practice of Clinical Trials
1
24
.
Jinze Li, Mayur S. Mitra & Gautham K. Rao. 2020. Immuno-Oncology. Immuno-Oncology
199
238
.
Honghui Zhou & Diane R. MouldPradeep B. Lukka, Santosh Wagh & Bernd Meibohm. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases
187
208
.
Anroop Nair, Mohamed Aly Morsy & Shery Jacob. (2018) Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Development Research 79:8, pages 373-382.
Crossref
Crossref
N Plock, S Vollert, M Mayer, G Hanauer & G Lahu. (2017) Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK‐648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction. Clinical and Translational Science 10:3, pages 185-193.
Crossref
Crossref
Vincent F. S. Dubois, Giovanni Smania, Huixin Yu, Ramona Graf, Anne S. Y. Chain, Meindert Danhof & Oscar Della Pasqua. (2016) Translating QT interval prolongation from conscious dogs to humans. British Journal of Clinical Pharmacology 83:2, pages 349-362.
Crossref
Crossref
E. Koch & S. Plassmann. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
7
38
.
L. Detalle, K. Vanheusden, M.L. Sargentini-Maier & T. Stöhr. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
495
529
.
M.P. Gleeson & D. Montanari. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
64
93
.
Haleh Saber, Ramadevi Gudi, Michael Manning, Emily Wearne & John K. Leighton. (2016) An FDA oncology analysis of immune activating products and first-in-human dose selection. Regulatory Toxicology and Pharmacology 81, pages 448-456.
Crossref
Crossref
Sherri Dudal, Heather Hinton, Anna M. Giusti, Marina Bacac, Magali Muller, Tanja Fauti, Sara Colombetti, Tobias Heckel, Nicolas Giroud, Christian Klein, Pablo Umaña, Lisa Benincosa, Juergen Bachl, Thomas Singer & Katharine Bray-French. (2016) Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. Journal of Immunotherapy 39:7, pages 279-289.
Crossref
Crossref
Klea Panayidou, Sandro Gsteiger, Matthias Egger, Gablu Kilcher, Máximo Carreras, Orestis Efthimiou, Thomas P. A. Debray, Sven Trelle & Noemi Hummel. (2016) GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world. Research Synthesis Methods 7:3, pages 264-277.
Crossref
Crossref
X Chen, N Haddish‐Berhane, P Moore, T Clark, Y Yang, H Li, D Xuan, HA Barton, AM Betts & F Barletta. (2016) Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach. Clinical Pharmacology & Therapeutics 100:3, pages 232-241.
Crossref
Crossref
Tarjinder Sahota, Meindert Danhof & Oscar Della Pasqua. (2016) Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. Mutagenesis 31:3, pages 359-374.
Crossref
Crossref
Jennifer J. Stewart, Cherie L. Green, Nicholas Jones, Meina Liang, Yuanxin Xu, Danice E. C. Wilkins, Maxime Moulard, Kamila Czechowska, David Lanham, Thomas W. McCloskey, John Ferbas, Barry. W. A. van der Strate, Carl‐Magnus Högerkorp, Timothy Wyant, Alan Lackey & Virginia Litwin. (2016) Role of receptor occupancy assays by flow cytometry in drug development. Cytometry Part B: Clinical Cytometry 90:2, pages 110-116.
Crossref
Crossref
Meina Liang, Martin Schwickart, Amy K. Schneider, Inna Vainshtein, Christopher Del Nagro, Nathan Standifer & Lorin K. Roskos. (2015) Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry Part B: Clinical Cytometry 90:2, pages 117-127.
Crossref
Crossref
Peng Zou, Sau Lee, Min Li, Lawrence Yu & Duxin Sun. 2016. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development
39
58
.
Marcel J. H. KenterAdam F. Cohen. (2015) The return of the prodigal son and the extraordinary development route of antibody TGN1412 ‐ lessons for drug development and clinical pharmacology. British Journal of Clinical Pharmacology 79:4, pages 545-547.
Crossref
Crossref
Andreas Reichel & Philip Lienau. 2016. New Approaches to Drug Discovery. New Approaches to Drug Discovery
235
260
.
David R. Jones & James W. McBlane. 2014. Mann's Pharmacovigilance. Mann's Pharmacovigilance
95
108
.
Tycho Heimbach, Rakesh Gollen & Handan He. 2014. Predictive ADMET. Predictive ADMET
319
352
.
Lasse Paludan Malver, Anne Brokjær, Camilla Staahl, Carina Graversen, Trine Andresen & Asbjørn Mohr Drewes. (2013) Electroencephalography and analgesics. British Journal of Clinical Pharmacology 77:1, pages 72-95.
Crossref
Crossref
Sandra A.G. Visser, Malin Aurell, Rhys D.O. Jones, Virna J.A. Schuck, Ann-Charlotte Egnell, Sheila A. Peters, Lena Brynne, James W.T. Yates, Rasmus Jansson-Löfmark, Beesan Tan, Marie Cooke, Simon T. Barry, Andrew Hughes & Ulf Bredberg. (2013) Model-based drug discovery: implementation and impact. Drug Discovery Today 18:15-16, pages 764-775.
Crossref
Crossref
Lucy C.J. Ellis, Gabrielle M. Hawksworth & Richard J. Weaver. (2013) ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicology and Applied Pharmacology 269:2, pages 187-194.
Crossref
Crossref
SAG Visser, E Manolis, M Danhof & T Kerbusch. (2013) Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development. CPT: Pharmacometrics & Systems Pharmacology 2:2, pages 1-3.
Crossref
Crossref
Christopher Horvath, Laura Andrews, Andreas Baumann, Lauren Black, Diann Blanset, Joy Cavagnaro, Kenneth L. Hastings, David L. Hutto, Timothy K. MacLachlan, Mark Milton, Theresa Reynolds, Stan Roberts, Mark Rogge, Jennifer Sims, George Treacy, Garvin Warner & James D. Green. (2012) Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nature Reviews Immunology 12:10, pages 740-740.
Crossref
Crossref
Anne Estrup Olesen, Trine Andresen, Camilla Staahl & Asbjørn Mohr Drewes. (2012) Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs. Pharmacological Reviews 64:3, pages 722-779.
Crossref
Crossref
J S Barrett, O Della Casa Alberighi, S Läer & B Meibohm. (2012) Physiologically Based Pharmacokinetic (PBPK) Modeling in Children. Clinical Pharmacology & Therapeutics 92:1, pages 40-49.
Crossref
Crossref
Peng Zou, Yanke Yu, Nan Zheng, Yongsheng Yang, Hayley J. Paholak, Lawrence X. Yu & Duxin Sun. (2012) Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. The AAPS Journal 14:2, pages 262-281.
Crossref
Crossref
Alexander V. LyubimovMeihua Rose Feng, Nan Zheng, Xinyuan Zhang, Yea Min Huh & Jing‐yu Yu. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Md Tarique Imam, S. P. Venkateshan, Monika Tandon, Nilanjan Saha & K. K. Pillai. (2011) Comparative Evaluation of US Food and Drug Administration and Pharmacologically Guided Approaches to Determine the Maximum Recommended Starting Dose for First-in-Human Clinical Trials in Adult Healthy Men. The Journal of Clinical Pharmacology 51:12, pages 1655-1664.
Crossref
Crossref
Ragini Vuppugalla, Punit Marathe, Handan He, Rhys D.O. Jones, James W.T. Yates, Hannah M. Jones, Christopher R. Gibson, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir Björnsson, Thierry Lavé & Patrick Poulin. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach. Journal of Pharmaceutical Sciences 100:10, pages 4111-4126.
Crossref
Crossref
Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Christopher R. Gibson, Malcolm Rowland, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Handan He, Ragini Vuppugalla, Punit Marathe, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir Björnsson, Thierry Lavé & James W.T. Yates. (2011) PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences 100:10, pages 4127-4157.
Crossref
Crossref
Hans Peter Grimm, Ying Ou, Micaela Reddy, Pascale David‐Pierson & Thierry Lavé. 2011. Systems Biology in Drug Discovery and Development. Systems Biology in Drug Discovery and Development
175
199
.
David Wexler & Kirk M. Bertelsen. (2013) A Brief Survey of First‐in‐Human Studies. The Journal of Clinical Pharmacology 51:7, pages 988-993.
Crossref
Crossref
John P. Gibbs. (2010) Prediction of Exposure–Response Relationships to Support First-in-Human Study Design. The AAPS Journal 12:4, pages 750-758.
Crossref
Crossref
Zvi Teitelbaum, Thierry Lave, Jan Freijer & Adam F. Cohen. (2010) Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans. Clinical Pharmacokinetics 49:9, pages 619-632.
Crossref
Crossref
Lorrene A. Buckley, Parag Garhyan, Rafael Ponce & Stanley A. Roberts. 2010. Early Drug Development. Early Drug Development
421
463
.
PJ Lowe. (2010) Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development. Clinical Pharmacology & Therapeutics 87:4, pages 492-496.
Crossref
Crossref
Jerry Nedelman, Frank Bretz, Roland Fisch, Anna Georgieva, Chyi‐Hung Hsu, Joseph Kahn, Ryosei Kawai, Phil Lowe, Jeff Maca, José Pinheiro, Anthony Rossini, Heinz Schmidli, Jean‐Louis Steimer & Jing Yu. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
29
.
Philip J. Lowe, Stacey Tannenbaum, Kai Wu, Peter Lloyd & Jennifer Sims. (2010) On Setting the First Dose in Man: Quantitating Biotherapeutic Drug‐Target Binding through Pharmacokinetic and Pharmacodynamic Models. Basic & Clinical Pharmacology & Toxicology 106:3, pages 195-209.
Crossref
Crossref
Patrick Y Muller, Mark Milton, Peter Lloyd, Jennifer Sims & Frank R Brennan. (2009) The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current Opinion in Biotechnology 20:6, pages 722-729.
Crossref
Crossref
Tycho Heimbach, Suresh B. Lakshminarayana, Wenyu Hu & Handan He. (2009) Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data. The AAPS Journal 11:3.
Crossref
Crossref
Vijay Sharma & John H McNeill. (2009) To scale or not to scale: the principles of dose extrapolation. British Journal of Pharmacology 157:6, pages 907-921.
Crossref
Crossref
Mark N. Milton & Christopher J. Horvath. (2009) The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development. Toxicologic Pathology 37:3, pages 363-371.
Crossref
Crossref
Christopher J. Horvath & Mark N. Milton. (2009) The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?. Toxicologic Pathology 37:3, pages 372-383.
Crossref
Crossref
PY Muller & FR Brennan. (2009) Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies. Clinical Pharmacology & Therapeutics 85:3, pages 247-258.
Crossref
Crossref
Balaji M. Agoram. (2009) Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics. British Journal of Clinical Pharmacology 67:2, pages 153-160.
Crossref
Crossref
Aberra Fura, Viral Vyas, William Humphreys, Anjaneya Chimalokonda & David Rodrigues. (2008) Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds. Biopharmaceutics & Drug Disposition 29:8, pages 455-468.
Crossref
Crossref
Punit H. Marathe, Christine Huang & A. David Rodrigues. 2008.
311
328
.